ResMed Inc. operates as a global leader in digital health and cloud-connected medical devices.
The company designs innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. The company's digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The company's comprehensive residential care software platform...
ResMed Inc. operates as a global leader in digital health and cloud-connected medical devices.
The company designs innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. The company's digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The company's comprehensive residential care software platforms support the professionals and caregivers who help people stay healthy in the home, or care setting of their choice. By enabling better care, the company's products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers, and healthcare systems.
The company also provides management software that assists durable, or home medical equipment (DME/HME) providers, and other long-term care providers operate more effectively and efficiently across various residential care settings. With a comprehensive set of software and services offerings, the company's software solutions enable providers to streamline workflow and deliver an improved patient experience across its existing vertical markets, including HME, and home infusion, facility-based organizations, including skilled nursing, senior living, and life plan communities, home health, and hospice providers, and to adjacent providers through a growing portfolio of value-added solutions with broad applicability.
In May 2025, the company acquired VirtuOx, a software-enabled independent diagnostic testing facility, or IDTF, and provider of technology solutions to facilitate in-home, and remote testing services for sleep, respiratory, cardiac, and other health conditions across the United States, or U.S. This acquisition strengthens the company's position in the sleep and breathing health market by expanding its ability to offer end-to-end solutions, including home-based diagnostics and patient monitoring.
The company sells its products in over 140 countries through a combination of wholly owned subsidiaries and independent distributors.
Segments
The company operates through two segments, Sleep and Breathing Health segment and Residential Care Software segment.
The company's Sleep and Breathing Health revenue relates primarily to the sale of its products that are therapy-based equipment. Some contracts include additional performance obligations, such as the provision of extended warranties and the provision of data for patient monitoring.
The company's Residential Care Software revenue relates to the provision of software access with ongoing support and maintenance services, as well as professional services, such as training and consulting.
Products
The company's portfolio of products includes devices, diagnostic products, mask systems, headgear, and other accessories, dental devices, and cloud-based software and informatics solutions. For purposes of the following discussion, the company generally refers to its air flow generators and ventilators collectively as devices.
Devices
The company produces cloud-connected CPAP, automatic positive airway pressure, or APAP, bilevel, adaptive servo-ventilation, or ASV, and HFT devices that deliver positive airway pressure through a patient interface, either a mask or cannula. The company's APAP, devices, known as AutoSet, are based on a patented technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA in some countries. During year 2017, the company launched AirMini, a small portable CPAP combining the same proven therapy modes used in the company's APAP devices with waterless humidification enabling portable convenience. During fiscal year 2021, the company launched its new platform of connected CPAP and APAP devices, AirSense 11, which introduced new features, such as a touch screen, algorithms for patients new to therapy, and digital enhancements, such as over-the-air update capabilities.
Mask Systems, Diagnostic Products, Accessories and Other Products
Mask Systems
Mask systems are one of the most important elements of sleep apnea treatment systems. Masks are a primary determinant of patient comfort and as such may drive or impede patient compliance with therapy. The company has been a consistent innovator in small nasal, nasal pillows, and full-face masks, by improving patient comfort while minimizing size and weight.
Minimalist: AirFit F40, AirFit F30, AirFit P10, and AirFit N30 minimalist masks feature the company's lightest, lowest profile designs. The features of these masks are focused on minimizing contact with the patient's face to reduce red marks and irritation.
Freedom: AirFit N30i, AirFit P30i, and AirFit F30i freedom masks, which feature top-of-head tubing design allowing flexibility to easily switch sleep positions.
Ultra Soft: The AirTouch F20 and AirTouch N20 masks feature a soft and breathable AirTouch cushion designed to enhance continuous positive airway pressure (CPAP) mask comfort.
Universal Fit: AirFit F20 and AirFit N20 masks are designed to fit a wide range of faces due to the InfinitySeal silicone cushion that adapts to unique facial contours, which increases comfort, improves the fit and reduces leakage.
Diagnostic Products
The company markets sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home. These diagnostic systems record relevant respiratory and sleep data, which can be analyzed by a sleep specialist or physician who can then tailor an appropriate obstructive sleep apnea (OSA) treatment regimen for the patient.
ApneaLink Air: A portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow and snoring. It works with AirView Diagnostics to provide comprehensive diagnostic solution to clinicians.
NightOwl: A portable, cloud-connected, fully disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
EasyCare Tx: A comprehensive sleep lab solution that treats a range of patients, designed to support comfortable, uninterrupted sleep for effective titration.
Connected Solutions and Other Products
The company has a suite of products that are designed to allow fewer professionals to manage more patients and empower patients to track their own health outcomes. The company is expanding its cloud-based patient management and engagement platforms, such as AirView, and other systems used by providers, enabling remote monitoring, over-the-air troubleshooting, changing of device settings, as well as automated patient coaching through a text, email, or interactive voice phone call, and myAir, a patient engagement application that provides sleep data, a daily score based on a user's previous night’s data, and coaching for patients.
AirView: A cloud-based system enabling remote monitoring and changing of patients' device settings. AirView also makes it easier to simplify workflows and collaborate more efficiently across patient care networks.
myAir: A personalized therapy management application for patients with sleep apnea providing support, education and troubleshooting tools for increased patient engagement and improved compliance.
Connectivity Module: A module providing a seamless cellular connection between the company's compatible ventilation devices (e.g., Astral, Stellar) and its AirView system.
Residential Care Software Products
The company provides Residential Care Software products designed to support the professionals and caregivers helping people stay healthy in the home, or care setting of their choice.
Brightree solutions: Brightree enables residential care organizations to improve their business performance and deliver better health outcomes. As an industry-leading cloud-based healthcare IT company, Brightree provides solutions and services for thousands of organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion.
HEALTHCAREfirst solutions: HEALTHCAREfirst offers electronic health record, or EHR, software, billing and coding services, and advanced analytics that enable home health and hospice agencies to optimize their clinical, financial and administrative processes.
MatrixCare solutions: MatrixCare’s EHR software as a service solutions are used by skilled nursing and senior living providers, life plan communities (CCRCs), and home health and hospice organizations to improve efficiencies and promote a better quality of life for the people they serve.
MEDIFOX DAN solutions: MEDIFOX DAN’s software solutions are used by residential care providers in Germany, especially home health and nursing home providers, and enable providers to achieve operating efficiencies and deliver better patient care and outcomes.
Product Development and Clinical Trials
The company's product development and clinical trial efforts are focused on not only improving its product offerings and usability and expanding into new digital product applications.
Across the sleep and breathing health platforms, the company supports clinical trials in many countries, including the U.S., Canada, Germany, France, the United Kingdom, Switzerland, Netherlands, Spain, Portugal, Sweden, Denmark, Iceland, Argentina, Chile, China, Republic of Korea, Japan, Malaysia, Singapore, and Australia to develop new clinical applications for its technology. The company also continues to support some of the largest sleep apnea studies in history by performing advanced statistical analyses on millions of real-world, de-identified, clinical data points collected through its cloud-connected devices and patient engagement tools.
Business Strategy
The key elements of the company's strategy include to grow and differentiate the company’s core sleep apnea portfolio; accelerate market growth through awareness; broader sleep and breathing health adjacencies; invest in an integrated, intelligent digital-health ecosystem delivered at home; and align solutions to enable smarter, connected care.
Sales and Marketing
The company markets its products in more than 140 countries through a network of distributors and direct sales staff.
United States, Canada, and Latin America: The company's products are typically purchased by an HME provider who then sells the products to the patient. The decision to purchase the company's products, as opposed to those of its competitors, is made or influenced by one or more of the following individuals or organizations: prescribing practitioners, HME providers, insurers (both private and public), and patients. In the U.S., Canada, and Latin America, the company's sales and marketing activities are conducted through a field sales organization made up of regional territory representatives, program development specialists, and regional sales directors. The field sales organization markets and sells products to HME provider branch locations throughout the U.S., Canada, and Latin America.
The company also directly educates physicians and sleep clinics about its products. Patients who are diagnosed with OSA or another respiratory condition and prescribed the company's products are typically referred by the diagnosing physician or sleep clinic to an HME provider to fill the prescription. The HME provider, in consultation with the referring practitioner, will assist the patient in selecting the equipment, fit the patient with the appropriate mask, and set the device pressure to the prescribed level.
The company's Residential Care Software solutions are sold to providers of healthcare in various residential care settings. The company markets and sells its Brightree business management software and service solutions to providers in the U.S. Its primary markets are HME, pharmacy, home infusion, orthotics, and prosthetics. The company's sales activities for Brightree products are conducted through an employee sales organization made up of strategic account managers, sales engineers, and sales directors. The company develops, markets, and sells its MatrixCare care management and related ancillary solutions to providers in the U.S., and its primary customers are senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations. The company's MatrixCare management solutions are primarily sold through direct sales, and ancillary solutions are sold both through direct sales and channel sellers.
Combined Europe, Asia, and other markets: The company markets its products in most major countries in combined Europe, Asia, and other geographies. The company has wholly owned subsidiaries in Australia, Austria, China, Czech Republic, Denmark, Finland, France, Germany, India, Ireland, Japan, Korea, Netherlands, New Zealand, Norway, Poland, Sweden, Switzerland, Taiwan, Thailand, and the United Kingdom. The company uses a combination of its direct sales force and independent distributors to sell its products in combined Europe, Asia, and other regions. The company selects independent distributors in each country based on their knowledge of respiratory medicine and a commitment to the treatment of sleep apnea with its therapy. In countries where the company sells its products directly, a local senior manager is responsible for direct national sales. In many countries, the company sells its products to HME providers or hospitals, who then sell the products to the patients. In Germany, Australia, New Zealand, and South Korea, the company also operates home healthcare businesses, providing products and services directly to patients through a vertically integrated network.
The company only sells its Residential Care Software products in the U.S. and Germany.
Competition
The company’s primary Sleep and Breathing Health competitors include Philips BV; Fisher & Paykel Healthcare Corporation Limited; DeVilbiss Healthcare; Apex Medical Corporation; BMC Medical Co. Ltd.; React Health Corporation; Jiangsu Yuyue Medical Equipment & Supply Co., Ltd, and Lowenstein Medical SE & Co. KG plus regional and new-entrant manufacturers.
Patents and Proprietary Rights and Related Litigation
Through its various subsidiaries, as of June 30, 2025, the company owns or has licensed rights to approximately 10,000 pending, allowed or granted patents and designs globally. Patents and designs have various statutory terms based on the legislation in individual jurisdictions which may be subject to change. Of the company’s patents and designs, approximately 640 U.S. patents and designs and approximately 1,450 foreign patents and designs are due to expire in the next five years.
Research and Development
For the year ended June 30, 2025, the company invested $331.3 million on research and development activities.
Government Regulations
The company's products are subject to extensive regulation particularly as to safety, efficacy and adherence to the Food and Drug Administration (FDA) Quality System Regulation, and related manufacturing standards. The FDA regulates the design, development, research, preclinical and clinical testing, introduction, manufacture, advertising, labeling, marking, packaging, marketing, distribution, import and export, and record keeping for the company's products, in order to ensure that medical products distributed in the United States are safe and effective for their intended use.
The company's devices marketed in the United States are marketed pursuant to 510(k) pre-marketing clearances and are either Class I or Class II devices. As a medical device manufacturer, all of the company's manufacturing facilities are subject to inspection on a routine basis by the FDA. The company is required to adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in the Quality System Regulation (QSR), which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the design and manufacturing process.
Where appropriate, the company's products commercialized in Europe are CE marked and classified as either Class I or Class II.
Any devices the company manufactures and distributes pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies.
The company's devices are sold in multiple countries and often need to be registered with local regulatory bodies, such as the Therapeutic Goods Administration in Australia, Health Canada in Canada and CFDA in China.
In some of its operations, such as those involving its cloud-based software digital health applications, the company is a business associate under Health Insurance Portability and Accountability Act of 1996 (HIPAA). The company is required to comply with the HIPAA Security Rule, Breach Notification Rule, and certain provisions of the HIPAA Privacy Rule. The company is limited by HIPAA with respect to its use and disclosure of protected health information created or received and could potentially face significant civil and criminal penalties if the Department of Health and Human Services Office for Civil Rights (OCR), or any state Attorney General, were to determine that the company failed to comply with the applicable HIPAA standards.
History
ResMed Inc. was founded in 1989. The company was incorporated in 1994.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
